Cancer / Immunology
PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existin...
January 24, 2024 | Regulatory
AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...
January 23, 2024 | News
Merck, a distinguished science and technology company, has announced groundbreaking real-world data that further solidify the JAVELIN Bladder regimen as a ...
January 23, 2024 | News
Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demo...
January 22, 2024 | News
BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, today announces a collaboration with Prisma Health aimed at a...
January 19, 2024 | News
In a pivotal stride toward advancing cancer care, Qure.ai, a leader in artificial intelligence (AI) solutions for medical imaging, and Project Data Sp...
January 19, 2024 | News
The CMS has established a national payment rate for RefleXion's SCINTIX® biology-guided radiotherapy using CMS' New Technology Ambulatory Payment Class...
January 16, 2024 | News
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...
January 16, 2024 | News
First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer Collaboration includes ex...
January 09, 2024 | News
The partnership expands Guardant Health's global presence and includes products across the cancer care continuum. The tests offered include Shield™ f...
January 09, 2024 | News
KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in...
January 05, 2024 | News
First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer Collaboration includes ex...
January 05, 2024 | News
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses t...
December 29, 2023 | News
The open-label, randomized, dose optimization phase 2 study aims to enroll participants in multiple countries to further clarify the optimal dosage...
December 29, 2023 | News
Most Read
Bio Jobs
News